Across two days in May, World Biosimilar Congress USA 2017 will gather together top biopharma to tackle common barriers in accessing the US biosimilars market such as high development costs, time-consuming R&D, and lengthy clinical trials. We're still working on our 2017 agenda, so we've included a look at what World Biosimilar Congress USA had to offer last year!
In 2016, we were joined by experts from across the biosimilars industry to discuss:
COMPETING IN THE BIOSIMILARS MARKET: PERSPECTIVE FROM A PURE PLAY COMPANY
BIOSIMILARS ON THE HORIZON: OPPORTUNITIES AND CHALLENGES IN THE UNITED STATES
COMPLEX BIOLOGICAL MODELS IN BIOSIMILAR DEVELOPMENT
THE EVOLVING BIOSIMILAR SECTOR: TRENDS AND IMPLICATIONS